AnaptysBio Files 8-K: Regulation FD & Financials
Ticker: ANAB · Form: 8-K · Filed: Oct 14, 2025 · CIK: 1370053
| Field | Detail |
|---|---|
| Company | Anaptysbio, Inc (ANAB) |
| Form Type | 8-K |
| Filed Date | Oct 14, 2025 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: 8-K, disclosure, financials
Related Tickers: ANAB
TL;DR
ANAB filed an 8-K on Oct 14, 2025, covering Reg FD and financials. Check it out.
AI Summary
AnaptysBio, Inc. filed an 8-K on October 14, 2025, reporting on events that occurred on or before that date. The filing includes information related to Regulation FD Disclosure and Financial Statements and Exhibits. The company is incorporated in Delaware and headquartered in San Diego, California.
Why It Matters
This 8-K filing provides updates on AnaptysBio's regulatory disclosures and financial statements, which are crucial for investors to understand the company's current standing and compliance.
Risk Assessment
Risk Level: low — This filing is a routine 8-K reporting standard disclosures and financial information, not indicating any immediate material adverse events.
Key Players & Entities
- ANAPTYSBIO, INC (company) — Registrant
- Delaware (jurisdiction) — State of Incorporation
- San Diego, CA (location) — Principal Executive Offices
- October 14, 2025 (date) — Date of Report
FAQ
What specific events triggered this 8-K filing?
The filing indicates it is for Regulation FD Disclosure and Financial Statements and Exhibits, suggesting these are the primary events being reported.
When was the earliest event reported in this filing?
The earliest event reported was on or before October 14, 2025.
What is AnaptysBio's principal executive office address?
The principal executive offices are located at 10770 Wateridge Circle, Suite 210, San Diego, CA 92121.
What is AnaptysBio's fiscal year end?
AnaptysBio's fiscal year ends on December 31.
What is the SIC code for AnaptysBio?
The Standard Industrial Classification (SIC) code for AnaptysBio is 2834, which corresponds to Pharmaceutical Preparations.
Filing Stats: 547 words · 2 min read · ~2 pages · Grade level 10 · Accepted 2025-10-14 16:33:51
Key Financial Figures
- $0.001 — ch registered Common Stock, par value $0.001 per share ANAB The Nasdaq Stock Marke
Filing Documents
- anab-20251014.htm (8-K) — 24KB
- anb033cd122antagonistinv.htm (EX-99.1) — 61KB
- anaptyscorporatepresenta.htm (EX-99.2) — 96KB
- anaptyscorporatepresenta001.jpg (GRAPHIC) — 84KB
- anaptyscorporatepresenta002.jpg (GRAPHIC) — 355KB
- anaptyscorporatepresenta003.jpg (GRAPHIC) — 174KB
- anaptyscorporatepresenta004.jpg (GRAPHIC) — 133KB
- anaptyscorporatepresenta005.jpg (GRAPHIC) — 87KB
- anaptyscorporatepresenta006.jpg (GRAPHIC) — 145KB
- anaptyscorporatepresenta007.jpg (GRAPHIC) — 176KB
- anaptyscorporatepresenta008.jpg (GRAPHIC) — 194KB
- anaptyscorporatepresenta009.jpg (GRAPHIC) — 212KB
- anaptyscorporatepresenta010.jpg (GRAPHIC) — 147KB
- anaptyscorporatepresenta011.jpg (GRAPHIC) — 146KB
- anaptyscorporatepresenta012.jpg (GRAPHIC) — 195KB
- anaptyscorporatepresenta013.jpg (GRAPHIC) — 182KB
- anaptyscorporatepresenta014.jpg (GRAPHIC) — 143KB
- anaptyscorporatepresenta015.jpg (GRAPHIC) — 188KB
- anaptyscorporatepresenta016.jpg (GRAPHIC) — 139KB
- anaptyscorporatepresenta017.jpg (GRAPHIC) — 251KB
- anaptyscorporatepresenta018.jpg (GRAPHIC) — 182KB
- anaptyscorporatepresenta019.jpg (GRAPHIC) — 144KB
- anaptyscorporatepresenta020.jpg (GRAPHIC) — 195KB
- anaptyscorporatepresenta021.jpg (GRAPHIC) — 218KB
- anaptyscorporatepresenta022.jpg (GRAPHIC) — 200KB
- anaptyscorporatepresenta023.jpg (GRAPHIC) — 178KB
- anaptyscorporatepresenta024.jpg (GRAPHIC) — 158KB
- anaptyscorporatepresenta025.jpg (GRAPHIC) — 183KB
- anaptyscorporatepresenta026.jpg (GRAPHIC) — 190KB
- anaptyscorporatepresenta027.jpg (GRAPHIC) — 160KB
- anaptyscorporatepresenta028.jpg (GRAPHIC) — 201KB
- anaptyscorporatepresenta029.jpg (GRAPHIC) — 176KB
- anaptyscorporatepresenta030.jpg (GRAPHIC) — 204KB
- anaptyscorporatepresenta031.jpg (GRAPHIC) — 146KB
- anaptyscorporatepresenta032.jpg (GRAPHIC) — 153KB
- anaptyscorporatepresenta033.jpg (GRAPHIC) — 200KB
- anaptyscorporatepresenta034.jpg (GRAPHIC) — 177KB
- anaptyscorporatepresenta035.jpg (GRAPHIC) — 261KB
- anaptyscorporatepresenta036.jpg (GRAPHIC) — 175KB
- anaptyscorporatepresenta037.jpg (GRAPHIC) — 139KB
- anaptyscorporatepresenta038.jpg (GRAPHIC) — 187KB
- anaptyscorporatepresenta039.jpg (GRAPHIC) — 192KB
- anaptyscorporatepresenta040.jpg (GRAPHIC) — 206KB
- anaptyscorporatepresenta041.jpg (GRAPHIC) — 181KB
- anaptyscorporatepresenta042.jpg (GRAPHIC) — 92KB
- anaptyscorporatepresenta043.jpg (GRAPHIC) — 126KB
- anaptyscorporatepresenta044.jpg (GRAPHIC) — 131KB
- anaptyscorporatepresenta045.jpg (GRAPHIC) — 176KB
- anaptyscorporatepresenta046.jpg (GRAPHIC) — 105KB
- anaptyscorporatepresenta047.jpg (GRAPHIC) — 147KB
- anaptyscorporatepresenta048.jpg (GRAPHIC) — 129KB
- anaptyscorporatepresenta049.jpg (GRAPHIC) — 174KB
- anaptyscorporatepresenta050.jpg (GRAPHIC) — 178KB
- anaptyscorporatepresenta051.jpg (GRAPHIC) — 169KB
- anaptyscorporatepresenta052.jpg (GRAPHIC) — 156KB
- anaptyscorporatepresenta053.jpg (GRAPHIC) — 149KB
- anaptyscorporatepresenta054.jpg (GRAPHIC) — 127KB
- anaptyscorporatepresenta055.jpg (GRAPHIC) — 145KB
- anaptyscorporatepresenta056.jpg (GRAPHIC) — 149KB
- anaptyscorporatepresenta057.jpg (GRAPHIC) — 147KB
- anaptyscorporatepresenta058.jpg (GRAPHIC) — 140KB
- anaptyscorporatepresenta059.jpg (GRAPHIC) — 133KB
- anaptyscorporatepresenta060.jpg (GRAPHIC) — 160KB
- anaptyscorporatepresenta061.jpg (GRAPHIC) — 132KB
- anaptyscorporatepresenta062.jpg (GRAPHIC) — 192KB
- anaptyscorporatepresenta063.jpg (GRAPHIC) — 195KB
- anaptyscorporatepresenta064.jpg (GRAPHIC) — 197KB
- anaptyscorporatepresenta065.jpg (GRAPHIC) — 141KB
- anaptyscorporatepresenta066.jpg (GRAPHIC) — 78KB
- anaptyscorporatepresenta067.jpg (GRAPHIC) — 157KB
- anaptyscorporatepresenta068.jpg (GRAPHIC) — 83KB
- anaptyscorporatepresenta069.jpg (GRAPHIC) — 185KB
- anaptyscorporatepresenta070.jpg (GRAPHIC) — 182KB
- anaptyscorporatepresenta071.jpg (GRAPHIC) — 160KB
- anaptyscorporatepresenta072.jpg (GRAPHIC) — 218KB
- anb033cd122antagonistinv001.jpg (GRAPHIC) — 151KB
- anb033cd122antagonistinv002.jpg (GRAPHIC) — 334KB
- anb033cd122antagonistinv003.jpg (GRAPHIC) — 177KB
- anb033cd122antagonistinv004.jpg (GRAPHIC) — 106KB
- anb033cd122antagonistinv005.jpg (GRAPHIC) — 105KB
- anb033cd122antagonistinv006.jpg (GRAPHIC) — 131KB
- anb033cd122antagonistinv007.jpg (GRAPHIC) — 144KB
- anb033cd122antagonistinv008.jpg (GRAPHIC) — 98KB
- anb033cd122antagonistinv009.jpg (GRAPHIC) — 126KB
- anb033cd122antagonistinv010.jpg (GRAPHIC) — 149KB
- anb033cd122antagonistinv011.jpg (GRAPHIC) — 176KB
- anb033cd122antagonistinv012.jpg (GRAPHIC) — 166KB
- anb033cd122antagonistinv013.jpg (GRAPHIC) — 163KB
- anb033cd122antagonistinv014.jpg (GRAPHIC) — 178KB
- anb033cd122antagonistinv015.jpg (GRAPHIC) — 169KB
- anb033cd122antagonistinv016.jpg (GRAPHIC) — 156KB
- anb033cd122antagonistinv017.jpg (GRAPHIC) — 149KB
- anb033cd122antagonistinv018.jpg (GRAPHIC) — 127KB
- anb033cd122antagonistinv019.jpg (GRAPHIC) — 145KB
- anb033cd122antagonistinv020.jpg (GRAPHIC) — 113KB
- anb033cd122antagonistinv021.jpg (GRAPHIC) — 169KB
- anb033cd122antagonistinv022.jpg (GRAPHIC) — 192KB
- anb033cd122antagonistinv023.jpg (GRAPHIC) — 195KB
- anb033cd122antagonistinv024.jpg (GRAPHIC) — 129KB
- anb033cd122antagonistinv025.jpg (GRAPHIC) — 89KB
- anb033cd122antagonistinv026.jpg (GRAPHIC) — 197KB
- anb033cd122antagonistinv027.jpg (GRAPHIC) — 99KB
- anb033cd122antagonistinv028.jpg (GRAPHIC) — 105KB
- anb033cd122antagonistinv029.jpg (GRAPHIC) — 147KB
- anb033cd122antagonistinv030.jpg (GRAPHIC) — 129KB
- anb033cd122antagonistinv031.jpg (GRAPHIC) — 174KB
- anb033cd122antagonistinv032.jpg (GRAPHIC) — 100KB
- anb033cd122antagonistinv033.jpg (GRAPHIC) — 121KB
- anb033cd122antagonistinv034.jpg (GRAPHIC) — 175KB
- anb033cd122antagonistinv035.jpg (GRAPHIC) — 148KB
- anb033cd122antagonistinv036.jpg (GRAPHIC) — 142KB
- anb033cd122antagonistinv037.jpg (GRAPHIC) — 141KB
- anb033cd122antagonistinv038.jpg (GRAPHIC) — 170KB
- anb033cd122antagonistinv039.jpg (GRAPHIC) — 124KB
- anb033cd122antagonistinv040.jpg (GRAPHIC) — 109KB
- anb033cd122antagonistinv041.jpg (GRAPHIC) — 114KB
- anb033cd122antagonistinv042.jpg (GRAPHIC) — 157KB
- anb033cd122antagonistinv043.jpg (GRAPHIC) — 126KB
- anb033cd122antagonistinv044.jpg (GRAPHIC) — 136KB
- anb033cd122antagonistinv045.jpg (GRAPHIC) — 164KB
- anb033cd122antagonistinv046.jpg (GRAPHIC) — 97KB
- anb033cd122antagonistinv047.jpg (GRAPHIC) — 149KB
- anb033cd122antagonistinv048.jpg (GRAPHIC) — 147KB
- anb033cd122antagonistinv049.jpg (GRAPHIC) — 154KB
- anb033cd122antagonistinv050.jpg (GRAPHIC) — 140KB
- anb033cd122antagonistinv051.jpg (GRAPHIC) — 133KB
- anb033cd122antagonistinv052.jpg (GRAPHIC) — 97KB
- anb033cd122antagonistinv053.jpg (GRAPHIC) — 160KB
- anb033cd122antagonistinv054.jpg (GRAPHIC) — 132KB
- anb033cd122antagonistinv055.jpg (GRAPHIC) — 141KB
- anb033cd122antagonistinv056.jpg (GRAPHIC) — 127KB
- 0001370053-25-000083.txt ( ) — 28087KB
- anab-20251014.xsd (EX-101.SCH) — 2KB
- anab-20251014_def.xml (EX-101.DEF) — 9KB
- anab-20251014_lab.xml (EX-101.LAB) — 29KB
- anab-20251014_pre.xml (EX-101.PRE) — 20KB
- anab-20251014_htm.xml (XML) — 3KB
01. Regulation FD
Item 7.01. Regulation FD. On October 14, 2025, AnaptysBio, Inc. ("AnaptysBio") will host a conference call to discuss ANB033 and use a slide presentation in conjunction with the call. A copy of the presentation is filed herewith as Exhibit 99.1. On October 14, 2025, AnaptysBio updated its corporate investor presentation, a full copy of which is attached hereto as Exhibit 99.2. The information in this Item 7.01, including Exhibits 99.1 and 99.2, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any other filing under the Exchange Act or the Securities Act of 1933, as amended, except as expressly set forth by specific reference in such a filing.
01. Financial Statements and Exhibits
Item 9.01. Financial Statements and Exhibits. (d) Exhibits Exhibit Number Exhibit Title or Description 99.1 AnaptysBio, Inc. Investor Presentation, dated October 14, 2025. 99.2 Anaptys Corporate Presentation October 2025. 104 Cover Page Interactive Data File (the cover page XBRL tags are embedded within the inline XBRL document).
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. AnaptysBio, Inc. Date: October 14, 2025 By: /s/ Dennis Mulroy Name: Dennis Mulroy Title: Chief Financial Officer